FDA clears Distalmotion's Dexter surgical robot for hysterectomy
Distalmotion received FDA 510(k) clearance for its Dexter robotic surgery system in total benign hysterectomy, removal of the ovaries and fallopian tubes, and other gynecologic procedures. It is Dexter's third U.S. indication, after inguinal hernia repair in October 2024 and gallbladder removal in May 2025. The company is targeting hospital outpatient departments and ambulatory surgery centers with a mobile robot that several specialties can share, and it says Dexter has been used in more than 2,000 procedures.
Why it's notable: Hysterectomy is one of the most common gynecologic operations and is moving to outpatient settings. A cheaper, shareable robot cleared for it adds competition to Intuitive's da Vinci for ambulatory surgery centers.